Summary
STICH3C is a prospective, multicentre, randomised controlled trial comparing contemporary percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with ischaemic left ventricular dysfunction and multivessel coronary artery disease. The trial aims to enrol 754 participants across approximately 45 international centres with 4–5 years median follow-up, directly addressing the evidence gap regarding optimal revascularisation strategy in this population. Results will inform clinical practice, patient decision-making, and international guideline development regarding efficacy and safety of PCI versus CABG in advanced ischaemic heart disease.
UK applicability
As an international multicentre trial including Canadian and European sites, findings will be directly applicable to UK cardiovascular practice and guideline development by the National Institute for Health and Care Excellence (NICE) and the British Cardiovascular Society. The trial's comparison of contemporary PCI techniques with CABG will inform treatment pathways for UK patients with ischaemic cardiomyopathy.
Key measures
Time-to-event analysis for composite endpoint (death, stroke, MI, urgent revascularisation, HF readmission); time to death; hospitalisation frequency for heart failure; major adverse events; quality-of-life measures; health economic data
Outcomes reported
The study measures a composite primary endpoint of death from any cause, stroke, spontaneous myocardial infarction, urgent repeat revascularisation, or heart failure readmission. Secondary outcomes include time to death, frequency of heart failure hospitalisations, major adverse events, disease-specific quality of life, and health economics measures.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.